Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared a post on X:
“At ASCO25, Dr. Helena Yu presented promising data for zipalertinib in previously treated EGFR ex20ins NSCLC
In this phase 1/2 study, zipalertinib showed:
ORR 35% (95% CI: 28–43%)
Clinical activity post-platinum ± amivantamab
ORR 24% even in the post-amivantamab group
CNS activity (ORR 31% in pts w/ brain mets)
Durable responses: median DOR 8.8 mo
Manageable safety, consistent with prior data
A potential option for a population with high unmet need. RESILIENT3, a phase 3 1L trial, is ongoing.”
More posts featuring Abner Antonio Murray.
